Provided by Tiger Trade Technology Pte. Ltd.

Nurix Therapeutics

25.10
-0.7100-2.75%
Post-market: 25.100.00000.00%16:04 EDT
Volume:1.32M
Turnover:33.60M
Market Cap:2.60B
PE:-7.36
High:26.65
Open:26.31
Low:25.00
Close:25.81
52wk High:28.23
52wk Low:8.20
Shares:103.41M
Float Shares:95.05M
Volume Ratio:1.11
T/O Rate:1.39%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4102
EPS(LYR):-3.0514
ROE:-80.30%
ROA:-40.06%
PB:6.45
PE(LYR):-8.23

Loading ...

Nurix CSO Gwenn Hansen Disposes of 1,452 Common Shares Worth $36,982.44

Reuters
·
Sep 02

Nurix Therapeutics to Participate in Upcoming September Investor Conferences

GlobeNewswire
·
Sep 01

Nurix Advances NX-5948 Combo Trial in B-Cell Cancers, Setting Up Key Catalyst for NRIX

TIPRANKS
·
Aug 29

BeOne Medicines' Tacabrutideg Presents 'Sizable Opportunity' in CSU, RBC Says

MT Newswires Live
·
Aug 25

Nurix Therapeutics Announces Appointment of Wes Burwell as Chief Human Resources Officer

THOMSON REUTERS
·
Aug 20

Nurix Therapeutics (NRIX) Starts Phase 3 And Lands Sanofi Milestone, Is The Valuation About Right?

Simply Wall St.
·
Aug 18

Nurix Therapeutics (NRIX) Is Up 6.0% After Milestone From Sanofi And Phase 3 Start With Roche

Simply Wall St.
·
Aug 13

Nurix Therapeutics' STAT6 Degrader Likely to Receive Increased Recognition, RBC Says

MT Newswires Live
·
Aug 11

Nurix Therapeutics is Maintained at Outperform by RBC Capital

Dow Jones
·
Aug 11

RBC Adjusts PT on Nurix Therapeutics to $36 From $33, Maintains Outperform Speculative Risk Rating

MT Newswires Live
·
Aug 10

How Investors May Respond To Nurix Therapeutics (NRIX) Advancing Bexobrutideg Into Registrational Phase 3 With Roche

Simply Wall St.
·
Aug 06

Nurix CSO Gwenn Hansen Sells 4,111 Shares for $100,068.32

Reuters
·
Aug 05

Nurix Therapeutics Price Target Maintained with a $34.00/Share by Needham

Dow Jones
·
Aug 04

Nurix Announces $10 Million Milestone Payment Associated with Initiation of a Phase 1 Clinical Trial of a Stat6 Degrader

THOMSON REUTERS
·
Aug 04

Nurix Therapeutics - Has Received About $139 Mln Under 2019 Sanofi Collaboration

THOMSON REUTERS
·
Aug 04

Nurix Therapeutics - Eligible for About $453 Mln in Future Stat6 Milestones and Potential Royalties

THOMSON REUTERS
·
Aug 04

Nurix Therapeutics Enrolls First Patient in Phase 3 Blood Cancer Trial

MT Newswires Live
·
Aug 04

Nurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 Daybreak Cll-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

THOMSON REUTERS
·
Aug 04

Nurix Therapeutics Chief Legal Officer Christine Ring Disposes of 16,589 Common Shares Worth $382,324.26

Reuters
·
Aug 04

Nurix Therapeutics is Maintained at Overweight by Morgan Stanley

Dow Jones
·
Jul 29